HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya RT @TBtrials_StAnd: “We MUST run faster than the diseases through prevention & management factoring multidisciplinary approaches collaborat…
NIMRMbeya Deputy Minister MoHCDGEC Dr. Faustine Ndugulile (sitted at the center) in a group photo with members of the Execu… https://t.co/g6GVYT9mu3
NIMRMbeya Deputy Minister MoHCDGEC Dr. Faustine Ndugulile giving a commencement speech for the annual PanACEA Consortium mee… https://t.co/p3XGG56KBd
NIMRMbeya RT @PanACEA_II: The 10th PanACEA Annual Meeting in Mbeya, TZ is officially opened by centre director Dr Ntingya, council chair Dr Mtasiwa,…
NIMRMbeya RT @SabiitiwWilber: The PanACEA 10th forum opens with exciting opening remarks from Dr Ntinginya, Prof Bouree, Prof Mgaya-NIMR director, NI…
© 2017 NIMR - Mbeya Medical Research Center